Anti-chemokine small molecule drugs: a promising future?
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
IMPORTANCE OF THE FIELD: Chemokines have principally been associated with inflammation due to their role in the control of leukocyte migration, but just over a decade ago chemokine receptors were also identified as playing a pivotal role in the entry of the HIV virus into cells. Chemokines activate seven transmembrane G protein-coupled receptors, making them extremely attractive therapeutic targets for the pharmaceutical industry. AREAS COVERED IN THIS REVIEW: Although there are now a large number of molecules targeting chemokines and chemokine receptors including neutralizing antibodies in clinical trials for inflammatory diseases, the results to date have not always been positive, which has been disappointing for the field. These failures have often been attributed to redundancy in the chemokine system. However, other difficulties have been encountered in drug discovery processes targeting the chemokine system, and these will be addressed in this review. WHAT THE READER WILL GAIN: In this review, the reader will get an insight into the hurdles that have to be overcome, learn about some of the pitfalls that may explain the lack of success, and get a glimpse of the outlook for the future. TAKE HOME MESSAGE: In 2007, the FDA approved maraviroc, an inhibitor of CCR5 for the prevention of HIV infection, the first triumph for a small-molecule drug acting on the chemokine system. The time to market, 11 years from discovery of CCR5, was fast by industry standards. A second small-molecule drug, a CXCR4 antagonist for hematopoietic stem cell mobilization, was approved by the FDA at the end of 2008. The results of a Phase III trial with a CCR9 inhibitor for Crohn's disease are also promising. This could herald the first success for a chemokine receptor antagonist as an anti-inflammatory therapeutic and confirms the importance of chemokine receptors as a target class for anti-inflammatory and autoimmune diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liu, R., Paxton, W. A., Choe, S., Ceradini, D., Martin, S. R., Horuk, R., MacDonald, M. E., Stuhlmann, H., Koup, R. A., & Landau, N. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80110-5 · Cited by 3,074
Boring, L., Gosling, J., Cleary, M., & Charo, I. F. (1998) · Nature · doi:10.1038/29788 · Cited by 1,965 · cited 1×
“However, certain knockout mice have refuted the notion of redundancy since deletion of one of the CCR2 ligands, JE, the murine equivalent of MCP-1/CCL2, results in a very similar phenotype to deletion of the receptor itself in disease models [8-11].”
BackgroundGerard, C., & Rollins, B. J. (2001) · Nature Immunology · doi:10.1038/84209 · Cited by 1,357
Exacerbations of multiple sclerosis in patients treated with gamma interferon
Panitch, H., Haley, A., Hirsch, R., & Johnson, K. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92863-7 · Cited by 1,071 · cited 1×
“The discrepancies between murine and human biology are not unique to the chemokine system: IFN-g treatment in myelin oligodendrocyte glycoprotein (MOG)induced EAE was shown to be protective [31], but when taken to the clinic, the administration of IFN-g to MS patients caused exacerbation of disease [32].”
BackgroundIzikson, L., Klein, R. S., Charo, I. F., Weiner, H. L., & Luster, A. D. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1075 · Cited by 584 · cited 1×
“However, certain knockout mice have refuted the notion of redundancy since deletion of one of the CCR2 ligands, JE, the murine equivalent of MCP-1/CCL2, results in a very similar phenotype to deletion of the receptor itself in disease models [8-11].”
BackgroundTrebst, C., Lykke Sørensen, T., Kivisäkk, P., Cathcart, M. K., Hesselgesser, J., Horuk, R., Sellebjerg, F., Lassmann, H., & Ransohoff, R. M. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63017-9 · Cited by 242
Furuichi, K., Gao, J.-L., Horuk, R., Wada, T., Kaneko, S., & Murphy, P. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.12.8670 · Cited by 100 · cited 1×
“However, in the mouse, CCR1 is expressed on neutrophils, and in the mouse CCL3 principally recruits these cells [38,39].”
Background
Cited by
The Chemokine Superfamily Revisited
Zlotnik, A., & Yoshie, O. (2012) · Immunity · doi:10.1016/j.immuni.2012.05.008 · Cited by 1,235
Anti-inflammatory Agents: Present and Future
Dinarello, C. A. (2010) · Cell · doi:10.1016/j.cell.2010.02.043 · Cited by 1,095
Haroon, E., Raison, C. L., & Miller, A. H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.205 · Cited by 1,000
Overcoming hurdles in developing successful drugs targeting chemokine receptors
Schall, T. J., & Proudfoot, A. E. I. (2011) · Nature Reviews Immunology · doi:10.1038/nri2972 · Cited by 318
Self-citationRole of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseases
Bose, S., & Cho, J. (2013) · Archives of Pharmacal Research · doi:10.1007/s12272-013-0161-z · Cited by 220
“Although no fruitful outcome has yet been achieved for this line of research, several anti-chemokine antibodies are currently under investigation to combat a variety of inflammatory pathologies, such as atherosclerosis, cancer and MS (Proudfoot et al. 2010).”
Background
Metadata
- Authors
- Proudfoot, A. E., Power, C. A., & Schwarz, M. K.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2010-01-29
- Volume
- 19
- Issue
- 3
- Pages
- 345-355
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2153417391
- Cited by
- 106
- References
- 7
- FWCI
- 8.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-chemokine small molecule drugs: a promising future? https://app.cochat.ai/papers/10.1517/13543780903535867
- The paper
- Proudfoot, A. E., Power, C. A., & Schwarz, M. K. (2010). Anti-chemokine small molecule drugs: a promising future? Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543780903535867
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.